CB-012 is under clinical development by Caribou Biosciences and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CB-012’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CB-012 overview

CB-012 is under development for the treatment of refractory or relapsed acute myeloid leukemia. The therapeutic candidate comprises of allogeneic T-cells genetically modified to express chimeric antigen receptor (CAR) that targets cells expressing c-type lectin-like molecule-1 (CLL-1). It is being developed based on Cas12a chRDNA platform.

Caribou Biosciences overview

Caribou Biosciences is a biopharmaceutical company that develops genome-edited allogeneic cell therapies for the treatment of cancer. It is investigating CB-010, an allogeneic anti-CD19 CAR-T (chimeric antigen receptor-T) cell therapy for B cell non-Hodgkin lymphoma; CB-011 drug against relapsed or refractory multiple myeloma; and CB-012 to treat acute myeloid leukemia (AML). The company is also evaluating CB-020, an iPSC-derived CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences utilizes its proprietary chRDNA (CRISPR hybrid RNA-DNA) technology to develop genome-edited cell therapies by enabling improved genome-editing precision. It works in collaboration with AbbVie Inc and The Leukemia & Lymphoma Society to research and develop CAR-T cell products. Caribou Biosciences is headquartered in Berkeley, California, the US.

For a complete picture of CB-012’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.